Moderna Inc (MRNA) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Moderna (MRNA) - corporate logo

The EV/EBITDA valuation trend for Moderna, Inc. (MRNA) is available for analysis on GURU.Markets, where 0.00 represents the latest metric reading. This price action reflects the transition toward cancer therapies and new vaccines, a unique mRNA platform accelerating development, and global trust in the pioneer brand. The technological superiority of Moderna, Inc. (MRNA) enables the company to effectively transform its business model following the decline in demand for COVID-19 vaccines.

Moderna Inc - MRNA Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/11/2026)

Summary analytical data breakdowns for modernatx.com (MRNA)

- current price and projected stock value:
Stock Price Moderna Corp|MRNA - Analyst Median Target
- market capitalization details:
Market Value Moderna Therapeutics|MRNA - Business Value
- book value of equity indicators:
Book Value per Share Moderna|MRNA - Net Asset Value|Market Capitalization to Book Value Ratio modernatx.com|MRNA - Company Assets
- company total debt and liquidity indicators:
Total Debt to Capital Moderna, Inc.|MRNA - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Moderna|MRNA - Company Cumulative Indebtedness|Debts to Book Capitalization Moderna Therapeutics|MRNA - Long-Term Debt Volume|Company Short-Term Debt Moderna|Quick Liquidity modernatx.com
- financial results and valuation multiples details:
MRNA - Company Profit|Expected Profit Moderna, Inc.|MRNA - Business Payback Period|Future Price to Earnings Moderna, Inc.|MRNA - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Moderna Therapeutics|MRNA - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) Moderna|MRNA - Earnings per share for the last 12 months|Quarterly EPS earnings growth modernatx.com|MRNA - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Moderna, Inc.
General company analysis:Moderna Corp MRNA
Product sample of Moderna Inc

Moderna, Inc. (MRNA) maintains stability through a strategy of co-investing in research alliances without pursuing costly acquisitions. The EV/EBITDA ratio compares the total enterprise value, including debt, with operating profit before depreciation and amortization. By analyzing the EV/EBITDA chart for Moderna, Inc. (MRNA), an investor can identify hidden credit risks or signs of asset undervaluation. A decline in this metric signals an increase in business efficiency relative to its market value.

Analysis of competing companies

EV/EBITDA Multiple SMMT (Summit Therapeutics Inc)|Total Company Value to Operating Income Before Depreciation Ratio SutroVax (PCVX)|TARS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CRMD (cormedix.com) - Enterprise Value to Operating Income Before Depreciation|MCRB: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio SPRO (Spero Therapeutics Inc)|SCYX (SCYNEXIS Inc) - EV/EBITDA Multiple|Company Value to EBITDA AN2 Bio ANTX|EV/EBITDA Multiple PYPD|Enterprise Value to EBITDA Ratio ysbiopharm.com LSB|Iterum Therapeutics - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio PHGE (BiomX Inc)|BioPharma Bio - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio 60 Degrees Pharmaceuticals SXTP|Oragenics, Inc. (OGEN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA opgen.com (OPGN)